| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327497 | Gynecologic Oncology | 2005 | 9 Pages |
Abstract
Based on survival and toxicity advantages and a once-monthly administration schedule, pegylated liposomal doxorubicin is the first-choice nonplatinum agent for relapsed ovarian cancer. Pegylated liposomal doxorubicin may also have clinical application in combination regimens for platinum-sensitive ovarian cancer, as consolidation/maintenance therapy for ovarian cancer, as a component of first-line therapy for ovarian cancer, and in the treatment of other gynecologic malignancies. Future clinical trials will further define and maximize the role of pegylated liposomal doxorubicin in the treatment of ovarian cancer and other gynecologic malignancies.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
J. Tate Thigpen, Carol A. Aghajanian, David S. Alberts, Susana M. Campos, Alan N. Gordon, Maurie Markman, D. Scott McMeekin, Bradley J. Monk, Peter G. Rose,